MRP2 mediated drug-drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting

International Journal of Pharmaceutics

Volumn 386, Issue 1-2, 2010, Pages 216-220

  Dahan, Arik ^a   Amidon, Gordon L ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Drug drug interaction; Efflux transport; Intestinal absorption; Molecular biopharmaceutics; Passive active GI wall permeability

Indexed keywords

INDOMETACIN; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN 2; SALAZOSULFAPYRIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG TARGETING; DRUG TRANSPORT; IC 50; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; INTESTINE SECRETION; JEJUNUM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE ABSORPTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; INDOMETHACIN; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; JEJUNUM; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PERMEABILITY; RATS; RATS, WISTAR; SULFASALAZINE;

EID: 74149085130     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.11.021     Document Type: Article

References (23)

1. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413
2. Dahan A., and Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur. J. Clin. Nutr. 58 (2004) 1
3. Dahan A., and Amidon G.L. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of P-glycoprotein. Pharm. Res. 26 (2009) 883-892
4. Dahan A., and Amidon G.L. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol. Pharm. 6 (2009) 19-28
5. Dahan A., and Amidon G.L. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am. J. Physiol. Gastrointest. Liver Physiol. 297 (2009) G371-G377
6. Dahan A., Sabit H., and Amidon G.L. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 11 (2009) 205-213
7. Dahan A., Sabit H., and Amidon G.L. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of P-gp and MRP2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab. Dispos. 37 (2009) 2028-2036
8. Dahan A., West B.T., and Amidon G.L. Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur. J. Pharm. Sci. 36 (2009) 320-329
9. El-Sheikh A.A.K., van den Heuvel J.J.M.W., Koenderink J.B., and Russel F.G.M. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 320 (2007) 229-235
10. Kim J.S., Mitchell S., Kijek P., Tsume Y., Hilfinger J., and Amidon G.L. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol. Pharm. 3 (2006) 686-694
11. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin. Pharmacokinet. 10 (1985) 285-302
12. Krishnamurthy P., and Schuetz J.D. Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 381-410
13. Kwon H., Lionberger R.A., and Yu L.X. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates. Mol. Pharm. 1 (2004) 455-465
14. Liang E., Proudfoot J., and Yazdanian M. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm. Res. 17 (2000) 1168-1174
15. Lindahl A., Sjoberg A., Bredberg U., Toreson H., Ungell A.-L., and Lennernas H. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of MRP2. Mol. Pharm. 1 (2004) 347-356
16. Martinez M.N., and Amidon G.L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 42 (2002) 620-643
17. Mols R., Deferme S., and Augustijns P. Sulfasalazine transport in in-vitro, ex-vivo and in-vivo absorption models: contribution of efflux carriers and their modulation by co-administration of synthetic nature-identical fruit extracts. J. Pharm. Pharmacol. 57 (2005) 1565-1573
18. Nozaki Y., Kusuhara H., Kondo T., Iwaki M., Shiroyanagi Y., Nakayama H., Horita S., Nakazawa H., Okano T., and Sugiyama Y. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther. 322 (2007) 1162-1170
19. Raub T.J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 3 (2006) 3-25
20. Sandborn W.J., and Hanauer S.B. The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther. 17 (2003) 29-42
21. Takano M., Yumoto R., and Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther. 109 (2006) 137
22. Yamasaki Y., Ieiri I., Kusuhara H., Sasaki T., Kimura M., Tabuchi H., Ando Y., Irie S., Ware J.A., Nakai Y., Higuchi S., and Sugiyama Y. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin. Pharmacol. Ther. 84 (2008) 95-103
23. Zaher H., Khan A.A., Palandra J., Brayman T.G., Yu L., and Ware J.A. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol. Pharm. 3 (2006) 55-61